Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.

Abstract: An immunogenic composition forming a vaccine includes a nanoparticle delivery system comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a nucleic acid encoding a protein from a coronavirus.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.

Abstract: The invention provides a method for treating a patient having human immunodeficiency virus (HIV) infection by determining whether the human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV and treating the patient based on that determination. In certain aspects, the methods comprise detecting whether the envelope protein from an HIV from the patient comprises a mutation or mutations in codons 117, 421, 121, and/or 298, wherein the presence of the mutation or mutations indicates that the HIV is likely to be more susceptible to the entry inhibitor than the reference HIV.

Abstract: The present invention provides methods for treating an individual having solid or lymphatic tumor comprising locally administering to the site of the tumor an oncolytic virus, and systemically administering an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor a second immunomodulator (including a combination of immunomodulators). Also provided are compositions and kits for the cancer therapy methods.

Abstract: A paramyxovirus vaccine strain for novel coronavirus pneumonia and a construction method thereof are provided. The method includes performing a recombination of N and F genes of Newcastle disease virus type VII of Paramyxoviridae with P, M, H, L genes of Canine distemper virus of Paramyxoviridae to obtain a recombinant virus, inserting S1 gene of the novel coronavirus between the P and M genes of the recombinant virus to obtain a recombinant vector. The vaccine strain constructed can stably and efficiently express the novel coronavirus S1 protein, and induce the body to produce antibodies; and the recombined virus vaccine strain can stimulate the human body to produce mucosal immunity, and the prepared vaccine can be vaccinated through a nasal spray. Moreover, the vaccine strain can be tested in poultry and dogs, saving time, reducing costs, and being more conducive to actual production due to large output.

Abstract: The present invention provides a virus-like particle comprising several or more types of HBs-L antigen proteins or a virus-like particle composition comprising a combination of the virus-like particles, for the purpose of provision of an antigen that triggers an immune reaction against HBV of various genotypes.

Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.

Abstract: The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.

Abstract: Provided herein, in some embodiments, are engineered phagemids that comprise at least one synthetic genetic circuit, wherein the at least one synthetic genetic circuit comprises gene sequences encoding at least one non-lytic antimicrobial peptides (AMPs) and/or antibacterial toxin proteins, a stable origin of replication, and a bacteriophage-packaging signal, wherein the engineered phagemid does not comprise some or all gene sequences encoding bacteriophage proteins required for assembly of a bacteriophage particle.

Abstract: The present invention relates to a nucleic acid molecule encoding a modified porcine epidemic diarrhea virus (PEDV) spike (S) protein and the PEDV (S) protein thereof. Further, the present invention relates to immunogenic compositions comprising said modified PEDV spike protein and methods for immunizing a subject comprising the administration of said immunogenic composition to a subject.

Abstract: A method of treating cancer in a subject in need thereof includes administering in situ to cancer cells of the subject a nanoparticle construct that includes a plurality of cowpea mosaic virus or virus-like particles electrostatically coupled to a plurality of G4 dendrimers having a different surface charge than the cowpea mosaic virus or virus-like particles. The nanoparticle construct upon delivery to a subject can provide a sustained release of the cowpea mosaic virus or virus-like particles and/or G4 dendrimers to a cell or tissue of the subject. The cancer selected from the group consisting of melanoma, breast cancer, colon cancer, lung cancer, and ovarian cancer.

Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.

Abstract: The present disclosure relates generally to genetically tagged bacterial delivery vehicles comprising unique tracer nucleic acid sequences (herein referred to as “tracers”) for use in detecting and/or quantitating the presence of two or more different said bacterial delivery vehicles within a mixture of vehicles. The present disclosure relates to methods wherein the bacterial delivery vehicles are detected through, for example, performance of multiple cycles of amplification using primers that bind to sequences within the unique tracer. Such methods can be advantageously used in quality control to detect and quantitate mixtures of bacterial delivery vehicles within a pharmaceutical composition.

Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.

Abstract: Provided is an oncolytic recombinant bacteriophage T7 expressing a cytokine in eukaryotic cells and displaying on its capsid a tumor specific homing peptide, thus inducing direct lysis of target tumor cells and immunological response to the phage leading to the effective anticancer effect. The phage naturally infecting bacteria, not human beings, provides a great advantage for gene manipulation and production for the development of anticancer agents.

Abstract: The disclosed disclosure is related to methods, compositions, and kits for targeting Adenovirus, nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers. Kits and methods comprise at least one of these oligomers. Methods include uniplex and multiplex amplification and detection reactions.

Abstract: Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.

Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.